Retifanlimab
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) . Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) [1].
Product Specifications
CAS Number
[2079108-44-2]
Product Name Alternative
INCMGA-00012; MGA-012
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/retifanlimab.html
Purity
96.84
Solubility
10 mM in DMSO
Smiles
[Retifanlimab]
Molecular Weight
(145.35 kDa)
References & Citations
[1]D V T Catenacci, et al. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open. 2022 Oct;7 (5) :100563.|[2]Shaukat A, et al. Retifanlimab: a breakthrough for the management of Merkel cell carcinoma[J]. IJS Oncology, 2023, 8 (3) : 18-20.|[3]La Motte-Mohs R, et al. Preclinical characterization of MGD013, a PD-1 x LAG-3 bispecific DART® molecule[J]. Lung, 2017, 28 (10/18) : 56.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
